The synthetic lethal screen with metabolic inhibitors identified preferential suppression of tumor cell proliferation by a combination of (R)-GNE-140 (an inhibitor of the lactate dehydrogenases (LDH) A/B) and the IDO1 inhibitor BMS-986205, which is currently tested in clinical trials. Here, IDO1 is linked to neoplasm.